S2Medical AB Total Liabilities

Latest as of June 2026: Skr6.84 Million SEK ≈ $735.66K USD

S2Medical AB total liabilities. Based on the latest financial reports, S2Medical AB (S2M) has total liabilities worth Skr6.84 Million SEK (≈ $735.66K USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See S2Medical AB defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Total Liabilities of S2Medical AB (2015–2025)

Total liabilities of S2Medical AB from 2015 to 2025. This chart illustrates how S2Medical AB's total liabilities have evolved over time, based on quarterly financial data.

S2Medical AB Competitors by Total Liabilities

The table below lists competitors of S2Medical AB ranked by their total liabilities.

Company Country Total Liabilities
Zapp Electric Vehicles Group Limited Ordinary Shares
NASDAQ:ZAPP
USA $27.91 Million
Valion Bio Inc
NASDAQ:VBIO
USA $20.59 Million
Steakholder Foods Ltd
NASDAQ:STKH
USA $877.00K
PURANIUM ENERGY LTD.
F:2DK
Germany €304.99K
Watkin Jones PLC
LSE:WJG
UK GBX165.03 Million
Christie Group plc
LSE:CTG
UK GBX24.79 Million
Jersey Oil and Gas PLC
LSE:JOG
UK GBX239.99K
Tongyang Inc
KO:001527
Korea ₩712.72 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down S2Medical AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see S2Medical AB total assets.

Liquidity & Leverage Metrics

S2Medical AB Total Liabilities Ratios Explained

S2Medical AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.58 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.68 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.40 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how S2Medical AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for S2Medical AB (2015–2025)

The table below shows the annual total liabilities of S2Medical AB from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 Skr7.03 Million
≈ $756.25K
+11.78%
2024-12-31 Skr6.29 Million
≈ $676.58K
-68.17%
2023-12-31 Skr19.75 Million
≈ $2.13 Million
+8.36%
2022-12-31 Skr18.22 Million
≈ $1.96 Million
+21.54%
2021-12-31 Skr15.00 Million
≈ $1.61 Million
+76.90%
2020-12-31 Skr8.48 Million
≈ $912.24K
+51.40%
2019-12-31 Skr5.60 Million
≈ $602.53K
+1.21%
2018-12-31 Skr5.53 Million
≈ $595.34K
+45.66%
2017-12-31 Skr3.80 Million
≈ $408.73K
+3.35%
2016-12-31 Skr3.67 Million
≈ $395.49K
+6.24%
2015-12-31 Skr3.46 Million
≈ $372.24K
--

About S2Medical AB

ST:S2M Sweden Medical Instruments & Supplies
Market Cap
$469.25K
Skr4.36 Million SEK
Market Cap Rank
#31089 Global
#727 in Sweden
Share Price
Skr0.00
Change (1 day)
+0.00%
52-Week Range
Skr0.00 - Skr0.01
All Time High
Skr1000000.00
About

S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden. The company offers odor eliminator under the YNOLENS brand; IvaQ, a negative pressure wound therapy (NPWT) system; Instagraft, a technology designed to make skin transplantation even in non-specialist healthcare setting; ADMERCIN, a solution against antibiotic-resistant bacteria; and… Read more